Helixgate

Helixgate

Uncategorized

Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal

Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast cancer medicine.

Read More

Published

on

Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast cancer medicine.

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Opinion: Why the space in ‘health care’ matters

Below is a lightly edited, AI-generated transcript of the “First Opinion Podcast” interview with Sarah Mupo. Be sure to sign up for the weekly “First Opinion Podcast” on Apple PodcastsSpotify, or wherever you get your podcasts. Get alerts about each new episode by signing up for the “First Opinion Podcast” newsletter. And don’t forget to sign up for the First Opinion newsletter, delivered every Sunday.

Torie Bosch: In recent years, there’s been a quiet shift in medicine. I’m not talking about a new drug or a new insurance headache. I’m talking about the way we write “health care.” Historically, it’s been two words. But increasingly, people, especially in the industry, have changed it to one word. At STAT, perhaps no linguistic decision is as important as: Should “health care” be one word or two?

Read the rest…

Read More

Published

on

Below is a lightly edited, AI-generated transcript of the “First Opinion Podcast” interview with Sarah Mupo. Be sure to sign up for the weekly “First Opinion Podcast” on Apple PodcastsSpotify, or wherever you get your podcasts. Get alerts about each new episode by signing up for the “First Opinion Podcast” newsletter. And don’t forget to sign up for the First Opinion newsletter, delivered every Sunday.

Torie Bosch: In recent years, there’s been a quiet shift in medicine. I’m not talking about a new drug or a new insurance headache. I’m talking about the way we write “health care.” Historically, it’s been two words. But increasingly, people, especially in the industry, have changed it to one word. At STAT, perhaps no linguistic decision is as important as: Should “health care” be one word or two?

Read the rest…

Read More

Continue Reading

Uncategorized

Denali sells FDA voucher for $195M to support neurodegenerative pipeline

Published

on

Denali Therapeutics is the latest company to sell a priority review fast pass for an elevated price after the program was renewed earlier this year.

Continue Reading

Uncategorized

US launches investigation into German drug pricing, citing unfair R&D burden

Published

on

The U.S. government has argued that it pays too much of biopharma R&D costs, demanding that other high-income countries contribute fairly to global innovation efforts.

Continue Reading
Advertisement

Trending